Results: Neo-adjuvant LCRT was administered to 142 patients for rectal cancer during this period; concurrent chemotherapy was omitted in 13 due to significant comorbidities. TNM stage was 2 or 3 radiologically at diagnosis in 127 (89.4%) of patients. At the time of LCRT 23% were taking a statin and 25% were taking aspirin.
Conclusion:
In contrast to other larger retrospective series, this study did not find improvements in toxicity or pCR rate through statin or aspirin use in rectal cancer patients undergoing LCRT. Their potential benefits in this setting would be best studied prospectively in a large randomised trial.
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Introduction
While advances in the management of rectal cancer have reduced local relapse to less than 10% in most patients, those with TNM tumour stage T4 and higher-risk T3 node-positive tumours still have higher local relapse rates. In addition, distant relapse still occurs in 25-30%, with a similar proportion dying within 5 years (1).
Statins are a class of drugs that inhibit the mevalonate pathway through inhibition of the rate-controlling enzyme, 3-hydroxy-3-methyl-glutaryl-CoA reductase. While they are commonly used to lower cholesterol, it appears that modulation of this signalling pathway may also improve cancer outcomes (2) . A Danish population study of 295,925 cancer cases diagnosed between 1995 and 2007 revealed that the use of statins significantly improved overall survival (OS) in the whole cohort, and specifically within the colorectal cancer (CRC) group (HR 0.79, 95% CI 0.74-0.85) (3).
Similarly a registry study of 17,115 CRC patients from Taiwan reported that multivariate cancer-specific mortality was significantly reduced in statin users (HR 0.77, p < 0.001)(4). More recently a population-based cohort study of 7657 patients with CRC in the United Kingdom showed that statin use improved CSS (fully adjusted HR, 0.71; 95% CI, 0.61 to 0.84) and all-cause mortality (fully adjusted HR, 0.75; 95% CI, 0.66 to 0.84) (5).
Preclinical studies have elaborated mechanisms that may contribute to improved cancer outcomes with statins, many of which relate to effects on cell signalling that are independent of cholesterol metabolism (6). These include mechanisms that can improve treatment efficacy as well as inhibition of radiation (RT)-induced gut and F o r P e e r R e v i e w skin toxicities (7) (8) (9) (10) (11) (12) (13) (14) . Thus there appears to be a specific and beneficial interaction of statins with RT. This correlates with retrospective clinical studies in which patients taking statins during chemo-RT for rectal cancer at Memorial Sloan-Kettering Cancer Center (n=349), Cleveland Clinic (n=407) or 5 Canadian hospitals (n=891) had significantly higher rates of pathological complete response (pCR) on multivariate analysis, ranging from 1.7 to 4.5 (15-17) . In contrast no benefit from statin use was seen in a large trial (n=842) of adjuvant chemotherapy for colon cancer (18). Furthermore, a prospective observational study of 308 patients at the Royal Marsden Hospital, London, treated with radical pelvic RT reported that those taking statins had significantly reduced RT-induced bowel toxicity, both during treatment (p=0.04) and one year later (19).
Aspirin's inhibition of platelet activation, platelet-tumour cell adhesion, angiogenesis and metastasis, as well as therapeutic interactions with chemotherapy and RT, have demonstrated survival benefits in CRC patients in some series (20-23) though not all (24). Interestingly, even though statins and aspirin may both improve outcomes through inhibiting inflammation, the benefit of statins is still seen when controlling for aspirin use (4) We retrospectively explored the potential benefit of using statin and/or aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) in the clinical setting of rectal 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w cancer patients receiving a standard course of neo-adjuvant long-course radiation therapy (LCRT) with concurrent chemotherapy (chemo-RT). We report the association of the use of statins and NSAIDS in this patient group with the acute toxicity of their treatment and the pCR rate found at the time of surgery. The electronic oncology notes prospectively recorded weekly toxicity evaluation (graded according to the Common Toxicity Criteria Version 3.0 (25)) during LCRT, hospital admissions or if treatment was stopped early due to toxicity. For the purposes of this study, the most severe bowel and bladder toxicity that developed during radiation treatment was documented. 16 and 7 with capecitabine, infusional and bolus 5FU respectively); 13 did not receive concurrent chemotherapy due to co-morbidities. Eleven patients (7.7%) were known to have metastatic disease at the time of diagnosis, of which nine had concurrent chemo-RT. Thirty three (23%) patients were taking a statin at the time of their LCRT (see Table 2 ), 28 using simvastatin and 5 using atorvastatin. Thirty-five (25%) patients were taking aspirin, 7 (5%) were taking other NSAIDs and 19 (13%) patients were taking both a statin and aspirin.
Methods
After completion of LCRT, only 140 patients went on to surgery as 2 patients died prior to their surgical procedure. In a further 5 patients the histological report was not obtainable and in all these cases their surgery was performed at a peripheral hospital. Of the 135 assessable patients, 17 (13%) achieved a pCR at the time of surgery. On logistic regression pCR was not significantly associated with the use of chemotherapy, statins, aspirin, other NSAIDs, T-stage or N-stage.
Prospectively-recorded data was available on bladder and rectal toxicity during RT in 141 patients. The most severe toxicity recorded was grade 3 for both bladder and rectum, in 1 and 19 (13.5%) patients respectively. Grade 1 and 2 bladder toxicities were recorded in 62 (44%) and 21 (14.9%) patients respectively, and grade 1 and 2 rectal toxicities in 40 (28.4%) and 72 (51.1%) patients respectively (Table 2) . Of the 129 patients who received concurrent chemotherapy, this treatment had to be There was no significant correlation between statin or aspirin use with bladder or rectal toxicity (Figure 1 ). Multinomial logistic regression was used to evaluate associations with grade of rectal toxicity: no interaction was seen with statin, aspirin or NSAID use, whereas chemotherapy was strongly associated with grade 3 toxicity (coefficient 15.3, p<0.00001). Actuarial time to maximum rectal toxicity was not different in statin users or non-users, when analysing either all patients (log-rank p=0.78) or those who had at least grade 2 toxicity (log-rank p= 0.44, Figure 2 ). On the background of this significant body of preclinical and clinical work supporting potential clinically-significant benefits of statin use during RT, the lack of benefit in toxicity or pCR rate with statins found in this retrospective study is most likely due to its significant limitations. This single centre study has a small sample size and it was not possible retrospectively to collect data on ECOG performance status or other factors such as pre-treatment CEA levels which have been associated with higher odds ratios for pCR (17). Similarly we were not able to evaluate a possible 
Discussion

Conclusion
Although our study did not find improvements in toxicity or pCR rate through statin or aspirin use in rectal cancer patients undergoing LCRT, the preclinical and clinical data collectively present a compelling case for such trials to be conducted, especially in cancer patients who are being treated with RT. Neo-adjuvant LCRT or chemo-RT in rectal cancer patients is a setting in which efficacy of statins in reducing toxicities can be combined with evaluating the histological, inflammatory and molecular effects of these agents in normal and malignant tissues. The implications of such a benefit at a population level are profound, offering improved tolerability of RT and better cancer outcomes, using agents that have very low cost and toxicity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Successful mitigation of delayed intestinal radiation injury using pravastatin is
